<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925351</url>
  </required_header>
  <id_info>
    <org_study_id>15-001600</org_study_id>
    <secondary_id>NCI-2016-01303</secondary_id>
    <secondary_id>15-001600</secondary_id>
    <nct_id>NCT02925351</nct_id>
  </id_info>
  <brief_title>Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases</brief_title>
  <official_title>The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography&#xD;
      (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory&#xD;
      diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by&#xD;
      inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to&#xD;
      measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan&#xD;
      may help to determine how fluorine F 18 clofarabine is distributed throughout the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine how fluorine F 18 clofarabine (18F-clofarabine) is distributed in the body, in&#xD;
      patients with autoimmune and inflammatory diseases.&#xD;
&#xD;
      II. Determine whether 18F-clofarabine can be used to image patients with autoimmune and&#xD;
      inflammatory diseases.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT&#xD;
      scan for up to 120 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2016</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>pilot</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized Uptake Value</measure>
    <time_frame>Baseline up to 240 minutes after injection</time_frame>
    <description>Standardized Uptake Value (SUV) will be the primary unit for assessment. Using standard PET/CT viewing software, the SUV will be measured for different organs and lesions of suspected disease and compared to reference/background tissues.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Autoimmune Disease</condition>
  <condition>Crohn Disease</condition>
  <condition>Inflammatory Disorder</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Takayasu Arteritis</condition>
  <arm_group>
    <arm_group_label>Imaging (fluorine F 18 clofarabine, PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Imaging (fluorine F 18 clofarabine, PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fluorine F 18 Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Imaging (fluorine F 18 clofarabine, PET/CT)</arm_group_label>
    <other_name>18F-CA</other_name>
    <other_name>18F-Clofarabine</other_name>
    <other_name>[18F]-Clofarabine</other_name>
    <other_name>Cl-18F-ara-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Imaging (fluorine F 18 clofarabine, PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be 18 years or older.&#xD;
&#xD;
          -  Diagnosed with an autoimmune and inflammatory disorder.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Women of childbearing age will have to undergo a pregnancy test that will be provided&#xD;
             free of charge.&#xD;
&#xD;
          -  Patients unable to undergo or comply with PET/CT scanning due to pre-existing medical&#xD;
             conditions including claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Allen-Auerbach</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

